COVID-19 vaccine

From Wikipedia the free encyclopedia

How COVID-19 vaccines work. The video shows the process of vaccination, from injection with RNA or viral vector vaccines, to uptake and translation, and on to immune system stimulation and effect.

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).

Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020.[1] The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness.[2] In January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by March 2020, the global pharmaceutical industry announced a major commitment to address COVID‑19.[3] In 2020, the first COVID‑19 vaccines were developed and made available to the public through emergency authorizations[4] and conditional approvals.[5][6] Initially, most COVID‑19 vaccines were two-dose vaccines, with the sole exception being the single-dose Janssen COVID-19 vaccine.[4] However, immunity from the vaccines has been found to wane over time, requiring people to get booster doses of the vaccine to maintain immunity against COVID‑19.[4]

The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19.[4][7] According to a June 2022 study, COVID‑19 vaccines prevented an additional 14.4 to 19.8 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021.[8][9] Many countries implemented phased distribution plans that prioritized those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers.[10]

Common side effects of COVID‑19 vaccines include soreness, redness, rash, inflammation at the injection site, fatigue, headache, myalgia (muscle pain), and arthralgia (joint pain), which resolve without medical treatment within a few days.[11][12] COVID-19 vaccination is safe for people who are breastfeeding.[13]

As of 22 September 2022, 12.7 billion doses of COVID‑19 vaccines have been administered worldwide based on official reports from national public health agencies.[14] By December 2020, more than 10 billion vaccine doses had been preordered by countries,[15] with about half of the doses purchased by high-income countries comprising 14% of the world's population.[16] Despite the extremely rapid development of effective mRNA and viral vector vaccines, worldwide vaccine equity has not been achieved. The development and use of whole inactivated virus (WIV) and protein-based vaccines have also been recommended, especially for use in developing countries.[17][18] The United States Food and Drug Administration (FDA) has now authorized bivalent vaccines to protect against the original COVID-19 strain and its Omicron variant.[19]


A US airman receiving a COVID‑19 vaccine, December 2020
Map of countries by approval status
  Approved for general use, mass vaccination underway
  EUA (or equivalent) granted, mass vaccination underway
  EUA granted, mass vaccination planned
  No data available

Prior to COVID‑19, a vaccine for an infectious disease had never been produced in less than several years – and no vaccine existed for preventing a coronavirus infection in humans.[20] However, vaccines have been produced against several animal diseases caused by coronaviruses, including (as of 2003) infectious bronchitis virus in birds, canine coronavirus, and feline coronavirus.[21] Previous projects to develop vaccines for viruses in the family Coronaviridae that affect humans have been aimed at severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Vaccines against SARS[22] and MERS[23] have been tested in non-human animals.

According to studies published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world at that time.[24][25][26] There is no cure or protective vaccine proven to be safe and effective against SARS in humans.[27][28] There is also no proven vaccine against MERS.[29] When MERS became prevalent, it was believed that existing SARS research might provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.[27][30] As of March 2020, there was one (DNA-based) MERS vaccine which completed Phase I clinical trials in humans,[31] and three others in progress, all being viral-vectored vaccines: two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA-vectored (MVA-MERS-S).[32]

Vaccines that use an inactive or weakened virus that has been grown in eggs typically take more than a decade to develop.[33][34] In contrast, mRNA is a molecule that can be made quickly, and research on mRNA to fight diseases was begun decades before the COVID‑19 pandemic by scientists such as Drew Weissman and Katalin Karikó, who tested on mice. Moderna began human testing of an mRNA vaccine in 2015.[33] Viral vector vaccines were also developed for the COVID‑19 pandemic after the technology was previously cleared for Ebola.[33]

As multiple COVID‑19 vaccines have been authorized or licensed for use, real-world vaccine effectiveness (RWE) is being assessed using case control and observational studies.[35][36] A study is investigating the long-lasting protection against SARS-CoV-2 provided by the mRNA vaccines.[37][38]

Vaccine technologies

Conceptual diagram showing three vaccine types for forming SARS‑CoV‑2 proteins to prompt an immune response: (1) RNA vaccine, (2) subunit vaccine, (3) viral vector vaccine
Vaccine platforms being employed for SARS-CoV-2. Whole virus vaccines include both attenuated and inactivated forms of the virus. Protein and peptide subunit vaccines are usually combined with an adjuvant in order to enhance immunogenicity. The main emphasis in SARS-CoV-2 vaccine development has been on using the whole spike protein in its trimeric form, or components of it, such as the RBD region. Multiple non-replicating viral vector vaccines have been developed, particularly focused on adenovirus, while there has been less emphasis on the replicating viral vector constructs.[39]

As of July 2021, at least nine different technology platforms are under research and development to create an effective vaccine against COVID‑19.[40][41] Most of the platforms of vaccine candidates in clinical trials are focused on the coronavirus spike protein (S protein) and its variants as the primary antigen of COVID‑19 infection,[40] since the S protein triggers strong B-cell and T-cell immune responses.[42][43] However, other coronavirus proteins are also being investigated for vaccine development, like the nucleocapsid, because they also induce a robust T-cell response and their genes are more conserved and recombine less frequently (compared to Spike).[43][44][45] Future generations of COVID-19 vaccines that may target more and conserved genomic regions will also act as an insurance against the manifestation of catastrophic scenarios concerning the future evolutionary path of SARS-CoV-2, or any similar Coronavirus epidemic/pandemic.[46]

Platforms developed in 2020 involved nucleic acid technologies (nucleoside-modified messenger RNA and DNA), non-replicating viral vectors, peptides, recombinant proteins, live attenuated viruses, and inactivated viruses.[20][40][47][48]

Many vaccine technologies being developed for COVID‑19 are not like vaccines already in use to prevent influenza, but rather are using "next-generation" strategies for precise targeting of COVID‑19 infection mechanisms.[40][47][48] Several of the synthetic vaccines use a 2P mutation to lock the spike protein into its prefusion configuration, stimulating an adaptive immune response to the virus before it attaches to a human cell.[49] Vaccine platforms in development may improve flexibility for antigen manipulation, and effectiveness for targeting mechanisms of COVID‑19 infection in susceptible population subgroups, such as healthcare workers, the elderly, children, pregnant women, and people with weakened immune systems.[40][47]

mRNA vaccines

Diagram of the operation of an RNA vaccine. Messenger RNA contained in the vaccine enters cells and is translated into foreign proteins, which trigger an immune response.

Several COVID‑19 vaccines, including the Pfizer–BioNTech and Moderna vaccines, have been developed to use RNA to stimulate an immune response. When introduced into human tissue, the vaccine contains either self-replicating RNA or messenger RNA (mRNA), which both cause cells to express the SARS-CoV-2 spike protein. This teaches the body how to identify and destroy the corresponding pathogen. RNA vaccines often, but not always, use nucleoside-modified messenger RNA. The delivery of mRNA is achieved by a coformulation of the molecule into lipid nanoparticles which protect the RNA strands and help their absorption into the cells.[50][51][52][53]

RNA vaccines are the first COVID‑19 vaccines to be authorized in the United Kingdom, the United States and the European Union.[54][55] Authorized vaccines of this type are the Pfizer–BioNTech[56][57][58] and Moderna vaccines.[59][60] The CVnCoV RNA vaccine from CureVac failed in clinical trials.[61]

Severe allergic reactions are rare. In December 2020, 1,893,360 first doses of Pfizer–BioNTech COVID‑19 vaccine administration resulted in 175 cases of severe allergic reaction, of which 21 were anaphylaxis.[62] For 4,041,396 Moderna COVID‑19 vaccine dose administrations in December 2020 and January 2021, only ten cases of anaphylaxis were reported.[62] Lipid nanoparticles (LNPs) were most likely responsible for the allergic reactions.[62]

Adenovirus vector vaccines

These vaccines are examples of non-replicating viral vector vaccines, using an adenovirus shell containing DNA that encodes a SARS‑CoV‑2 protein.[63][64] The viral vector-based vaccines against COVID‑19 are non-replicating, meaning that they do not make new virus particles, but rather produce only the antigen which elicits a systemic immune response.[63]

Authorized vaccines of this type are the Oxford–AstraZeneca COVID‑19 vaccine,[65][66][67] the Sputnik V COVID‑19 vaccine,[68] Convidecia, and the Janssen COVID‑19 vaccine.[69][70]

Convidecia and the Janssen COVID‑19 vaccine are both one-shot vaccines which offer less complicated logistics and can be stored under ordinary refrigeration for several months.[71][72]

Sputnik V uses Ad26 for its first dose, which is the same as Janssen's only dose, and Ad5 for the second dose, which is the same as Convidecia's only dose.[73]

In August 2021, the developers of Sputnik V proposed, in view of the Delta case surge, that Pfizer test the Ad26 component (termed its 'Light' version)[74] as a booster shot:

Delta cases surge in US & Israel shows mRNA vaccines need a heterogeneous booster to strengthen & prolong immune response. #SputnikV pioneered mix&match approach, combo trials & showed 83.1% efficacy vs Delta. Today RDIF offers Pfizer to start trial with Sputnik Light as booster.[75]

Inactivated virus vaccines

Inactivated vaccines consist of virus particles that are grown in culture and then killed using a method such as heat or formaldehyde to lose disease producing capacity, while still stimulating an immune response.[76]

Authorized vaccines of this type are the Chinese CoronaVac[77][78][79] and the Sinopharm BIBP[80] and WIBP vaccines; the Indian Covaxin; later this year the Russian CoviVac;[81] the Kazakh vaccine QazVac;[82] and the Iranian COVIran Barekat.[83] Vaccines in clinical trials include the Valneva COVID‑19 vaccine.[84][unreliable source?][85]

Subunit vaccines

Subunit vaccines present one or more antigens without introducing whole pathogen particles. The antigens involved are often protein subunits, but can be any molecule that is a fragment of the pathogen.[86]

The authorized vaccines of this type are the peptide vaccine EpiVacCorona,[87] ZF2001,[41] MVC-COV1901,[88] Corbevax,[89][90] and the Sanofi–GSK vaccine.[91][92] Vaccines with pending authorizations include the Novavax COVID‑19 vaccine,[93] and Soberana 02 (a conjugate vaccine).[citation needed]

The V451 vaccine was in clinical trials that were terminated after it was found that the vaccine may potentially cause incorrect results for subsequent HIV testing.[94][95][unreliable source?]

Other types

Additional types of vaccines that are in clinical trials include virus-like particle vaccines, multiple DNA plasmid vaccines,[96][97][98][99][100][101] at least two lentivirus vector vaccines,[102][103] a conjugate vaccine, and a vesicular stomatitis virus displaying the SARS‑CoV‑2 spike protein.[104]

Scientists investigated whether existing vaccines for unrelated conditions could prime the immune system and lessen the severity of COVID‑19 infection.[105] There is experimental evidence that the BCG vaccine for tuberculosis has non-specific effects on the immune system, but no evidence that this vaccine is effective against COVID‑19.[106]

List of authorized vaccines

COVID-19 vaccines authorized for emergency use or approved for full use
Common name Type (technology) Country of origin First authorization Notes
Authorized in more than 10 countries
Oxford–AstraZeneca Adenovirus vector United Kingdom, Sweden December 2020
Pfizer–BioNTech RNA Germany, United States December 2020 Both original and Omicron variant versions
Janssen Adenovirus vector United States, Netherlands February 2021
Moderna RNA United States December 2020 Both original and Omicron variant versions
Sinopharm BIBP Inactivated China July 2020
Sputnik V Adenovirus vector Russia August 2020
CoronaVac Inactivated China August 2020
Novavax Subunit/virus-like particle United States December 2021
Covaxin Inactivated India January 2021
Valneva Inactivated France, Austria April 2022
Sanofi–GSK Subunit France, United Kingdom November 2022 Based on Beta variant
Sputnik Light Adenovirus vector Russia May 2021
Authorized in 2–10 countries
Convidecia Adenovirus vector China June 2020
Sinopharm WIBP Inactivated China February 2021
Abdala Subunit Cuba July 2021
EpiVacCorona Subunit Russia October 2020
Zifivax Subunit China March 2021
Soberana 02 Subunit Cuba, Iran June 2021
CoviVac Inactivated Russia February 2021
Medigen Subunit Taiwan July 2021
QazCovid-in Inactivated Kazakhstan April 2021
Minhai Inactivated China May 2021
COVIran Barekat Inactivated Iran June 2021
Soberana Plus Subunit Cuba August 2021
Corbevax Subunit India, United States December 2021
Authorized in 1 country
Chinese Academy of Medical Sciences Inactivated China June 2021
ZyCoV-D DNA India August 2021
FAKHRAVAC Inactivated Iran September 2021
COVAX-19 Subunit Australia, Iran October 2021
Razi Cov Pars Subunit Iran October 2021
Turkovac Inactivated Turkey December 2021
Sinopharm CNBG Subunit China December 2021 Based on original, Beta, and Kappa variants
CoVLP Virus-like particle Canada, United Kingdom February 2022
Noora Subunit Iran March 2022
Skycovione Subunit South Korea June 2022
Walvax RNA China September 2022
iNCOVACC Adenovirus vector India September 2022 Nasal vaccine
V-01 Subunit China September 2022
Gemcovac RNA India October 2022 Self-amplifying RNA vaccine
IndoVac Subunit Indonesia October 2022

Delivery methods

Currently, all coronavirus vaccines available, regardless of the different types of technology they are based on, are administrated by injection. However, various other types of vaccine delivery methods have been studied for future coronavirus vaccines.[107]


Intranasal vaccines target mucosal immunity in the nasal mucosa which is a portal for viral entrance to the body.[108][109] These vaccines are designed to stimulate nasal immune factors, such as IgA.[108] In addition to inhibiting the virus, nasal vaccines provide ease of administration because no needles (and the accompanying needle phobia) are involved.[109][110] Nasal vaccines have been approved for influenza,[109][110] but not for COVID-19.

A variety of intranasal COVID-19 vaccines are undergoing clinical trials. One is in use in China.[111] Examples include a vaccine candidate which uses a modified avian virus as a vector to target SARS-CoV-2 spike proteins and an mRNA vaccine delivered via a nasal nanoparticle spray.[112] In September 2022, India and China approved the two first nasal COVID-19 vaccines which may (as boosters)[113] also reduce transmission[114][115] (potentially via sterilizing immunity).[114]


Aivita Biomedical is developing an experimental autologous dendritic cell COVID‑-19 vaccine kit where the vaccine is prepared and incubated at the point-of-care using cells from the intended recipient.[116] The vaccine is undergoing small phase I and phase II clinical studies.[116][117][118]

Universal vaccine

A universal coronavirus vaccine is effective against all coronavirus (and possibly other) viruses.[119][120] The concept was publicly endorsed by NIAID director Anthony Fauci, virologist Jeffery K. Taubenberger, and David M. Morens.[121] In March 2022, the White House released the "National COVID-19 Preparedness Plan", which recommended to accelerate development of such vaccines.[122]

One strategy for developing such vaccines was developed at Walter Reed Army Institute of Research (WRAIR). It uses a spike ferritin-based nanoparticle (SpFN). This vaccine began a Phase I clinical trial in April 2022.[123]

Another strategy is to attach vaccine fragments from multiple strains to a nanoparticle scaffold. Universality is enhanced by targeting the receptor-binding domain rather than the spike protein.[124]


As of September 2020, eleven of the vaccine candidates in clinical development use adjuvants to enhance immunogenicity.[40] An immunological adjuvant is a substance formulated with a vaccine to elevate the immune response to an antigen, such as the COVID‑19 virus or influenza virus.[125] Specifically, an adjuvant may be used in formulating a COVID‑19 vaccine candidate to boost its immunogenicity and efficacy to reduce or prevent COVID‑19 infection in vaccinated individuals.[125][126] Adjuvants used in COVID‑19 vaccine formulation may be particularly effective for technologies using the inactivated COVID‑19 virus and recombinant protein-based or vector-based vaccines.[126] Aluminum salts, known as "alum", were the first adjuvant used for licensed vaccines, and are the adjuvant of choice in some 80% of adjuvanted vaccines.[126] The alum adjuvant initiates diverse molecular and cellular mechanisms to enhance immunogenicity, including release of proinflammatory cytokines.[125][126]

Planning and development

Since January 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments.[40]

Multiple steps along the entire development path are evaluated, including:[20][127]

  • the level of acceptable toxicity of the vaccine (its safety),
  • targeting vulnerable populations,
  • the need for vaccine efficacy breakthroughs,
  • the duration of vaccination protection,
  • special delivery systems (such as oral or nasal, rather than by injection),
  • dose regimen,
  • stability and storage characteristics,
  • emergency use authorization before formal licensing,
  • optimal manufacturing for scaling to billions of doses, and
  • dissemination of the licensed vaccine.


There have been several unique challenges with COVID‑19 vaccine development.

The urgency to create a vaccine for COVID‑19 led to compressed schedules that shortened the standard vaccine development timeline, in some cases combining clinical trial steps over months, a process typically conducted sequentially over several years.[128] Public health programs have been described as in "[a] race to vaccinate individuals" with the early wave vaccines.[129]

Timelines for conducting clinical research – normally a sequential process requiring years – are being compressed into safety, efficacy, and dosing trials running simultaneously over months, potentially compromising safety assurance.[128][130] As an example, Chinese vaccine developers and the government Chinese Center for Disease Control and Prevention began their efforts in January 2020,[131] and by March were pursuing numerous candidates on short timelines, with the goal to showcase Chinese technology strengths over those of the United States, and to reassure the Chinese people about the quality of vaccines produced in China.[128][132]

The rapid development and urgency of producing a vaccine for the COVID‑19 pandemic was expected to increase the risks and failure rate of delivering a safe, effective vaccine.[47][48][133] Additionally, research at universities is obstructed by physical distancing and closing of laboratories.[134][135]

Vaccines must progress through several phases of clinical trials to test for safety, immunogenicity, effectiveness, dose levels and adverse effects of the candidate vaccine.[136][137] Vaccine developers have to invest resources internationally to find enough participants for Phase II–III clinical trials when the virus has proved to be a "moving target" of changing transmission rates across and within countries, forcing companies to compete for trial participants.[138] Clinical trial organizers also may encounter people unwilling to be vaccinated due to vaccine hesitancy[139] or disbelief in the science of the vaccine technology and its ability to prevent infection.[140] As new vaccines are developed during the COVID‑19 pandemic, licensure of COVID‑19 vaccine candidates requires submission of a full dossier of information on development and manufacturing quality.[141][142][143]


Internationally, the Access to COVID‑19 Tools Accelerator is a G20 and World Health Organization (WHO) initiative announced in April 2020.[144][145] It is a cross-discipline support structure to enable partners to share resources and knowledge. It comprises four pillars, each managed by two to three collaborating partners: Vaccines (also called "COVAX"), Diagnostics, Therapeutics, and Health Systems Connector.[146] The WHO's April 2020 "R&D Blueprint (for the) novel Coronavirus" documented a "large, international, multi-site, individually randomized controlled clinical trial" to allow "the concurrent evaluation of the benefits and risks of each promising candidate vaccine within 3–6 months of it being made available for the trial." The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonized Phase III protocols for all vaccines achieving the pivotal trial stage.[147]

National governments have also been involved in vaccine development. Canada announced funding of 96 projects for development and production of vaccines at Canadian companies and universities with plans to establish a "vaccine bank" that could be used if another coronavirus outbreak occurs,[148] and to support clinical trials and develop manufacturing and supply chains for vaccines.[149]

China provided low-rate loans to one vaccine developer through its central bank, and "quickly made land available for the company" to build production plants.[130] Three Chinese vaccine companies and research institutes are supported by the government for financing research, conducting clinical trials, and manufacturing.[150]

The United Kingdom government formed a COVID‑19 vaccine task force in April 2020 to stimulate local efforts for accelerated development of a vaccine through collaborations of industry, universities, and government agencies. The UK's Vaccine Taskforce contributed to every phase of development from research to manufacturing.[151]

In the United States, the Biomedical Advanced Research and Development Authority (BARDA), a federal agency funding disease-fighting technology, announced investments to support American COVID‑19 vaccine development, and manufacture of the most promising candidates.[130][152] In May 2020, the government announced funding for a fast-track program called Operation Warp Speed.[153][154] By March 2021, BARDA had funded an estimated $19.3 billion in COVID‑19 vaccine development.[155]

Large pharmaceutical companies with experience in making vaccines at scale, including Johnson & Johnson, AstraZeneca, and GlaxoSmithKline (GSK), formed alliances with biotechnology companies, governments, and universities to accelerate progression toward effective vaccines.[130][128]

Clinical research

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:[156][157]

As of June 2022, 353 vaccine candidates are in various stages of development, with 135 in clinical research, including 38 in phase I trials, 32 in phase I–II trials, 39 in phase III trials, and 9 in phase IV development.[156]

Post-vaccination complications

Post-vaccination embolic and thrombotic events, termed vaccine-induced immune thrombotic thrombocytopenia (VITT),[158][159][160][161][162] vaccine-induced prothrombotic immune thrombocytopenia (VIPIT),[163] thrombosis with thrombocytopenia syndrome (TTS),[164][161][162] vaccine-induced immune thrombocytopenia and thrombosis (VITT),[162] or vaccine-associated thrombotic thrombocytopenia (VATT),[162] are rare types of blood clotting syndromes that were initially observed in a number of people who had previously received the Oxford–AstraZeneca COVID‑19 vaccine (AZD1222)[a] during the COVID‑19 pandemic.[163][169] It was subsequently also described in the Janssen COVID‑19 vaccine (Johnson & Johnson) leading to suspension of its use until its safety had been reassessed.[170] On 5 May 2022 the FDA posted a bulletin limiting the use of the Janssen Vaccine to very specific cases due to further reassesment of the risks of TTS, although the FDA also stated in the same bulletin that the benefits of the vaccine outweigh the risks.[171]

In April 2021, AstraZeneca and the European Medicines Agency (EMA) updated their information for healthcare professionals about AZD1222, saying it is "considered plausible" that there is a causal relationship between the vaccination and the occurrence of thrombosis in combination with thrombocytopenia and that, "although such adverse reactions are very rare, they exceeded what would be expected in the general population".[169][172][173][174]


COVID‑19 vaccine research samples in a NIAID lab freezer (30 January 2020)

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19, was isolated in late 2019.[175] Its genetic sequence was published on 11 January 2020, triggering the urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine.[176][177][178] Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments.[179] By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection.[177][180][181][182] According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.[176][179]

In February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS‑CoV‑2 to become available in less than 18 months.[183] Virologist Paul Offit commented that, in hindsight, the development of a safe and effective vaccine within 11 months was a remarkable feat.[184] The rapidly growing infection rate of COVID‑19 worldwide during 2020 stimulated international alliances and government efforts to urgently organize resources to make multiple vaccines on shortened timelines,[185] with four vaccine candidates entering human evaluation in March (see COVID-19 vaccine § Trial and authorization status).[176][186]

On 24 June 2020, China approved the CanSino vaccine for limited use in the military, and two inactivated virus vaccines for emergency use in high-risk occupations.[187] On 11 August 2020, Russia announced the approval of its Sputnik V vaccine for emergency use, though one month later only small amounts of the vaccine had been distributed for use outside of the phase 3 trial.[188]

The Pfizer–BioNTech partnership submitted an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for the mRNA vaccine BNT162b2 (active ingredient tozinameran) on 20 November 2020.[189][190] On 2 December 2020, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) gave temporary regulatory approval for the Pfizer–BioNTech vaccine,[191][192] becoming the first country to approve the vaccine and the first country in the Western world to approve the use of any COVID‑19 vaccine.[193][194][195] As of 21 December 2020, many countries and the European Union[196] had authorized or approved the Pfizer–BioNTech COVID‑19 vaccine. Bahrain and the United Arab Emirates granted emergency marketing authorization for the Sinopharm BIBP vaccine.[197][198] On 11 December 2020, the FDA granted an EUA for the Pfizer–BioNTech COVID‑19 vaccine.[199] A week later, they granted an EUA for mRNA-1273 (active ingredient elasomeran), the Moderna vaccine.[200][201][202][203]

On 31 March 2021, the Russian government announced that they had registered the first COVID‑19 vaccine for animals.[204] Named Carnivac-Cov, it is an inactivated vaccine for carnivorous animals, including pets, aimed at preventing mutations that occur during the interspecies transmission of SARS-CoV-2.[205]

In October 2022 China began administering an oral vaccine developed by CanSino Bioligics, using its adenovirus model.[206]

Despite the availability of mRNA and viral vector vaccines, worldwide vaccine equity has not been achieved. The ongoing development and use of whole inactivated virus (WIV) and protein-based vaccines has been recommended, especially for use in developing countries, to dampen further waves of the pandemic.[207][208]

In November 2021, the full nucleotide sequences of the AstraZeneca and Pfizer/BioNTech vaccines were released by the UK Medicines and Healthcare products Regulatory Agency, in response to a freedom of information request.[209][210]


As of August 2021, studies reported that the COVID-19 vaccines available in the United States are "highly protective against severe illness, hospitalization, and death due to COVID-19".[211] In comparison with fully vaccinated people, the CDC reported that unvaccinated people were 10 times more likely to be hospitalized and 11 times more likely to die.[212][213]

Dr. Jeff Duchin, the Health Officer of King County, Washington found that unvaccinated people were six times more likely to test positive, 37 times more likely to be hospitalized, and 67 times more likely to die, compared to those who had been vaccinated.[214]

CDC reported that vaccine effectiveness fell from 91% against Alpha to 66% against Delta.[215] One expert stated that "those who are infected following vaccination are still not getting sick and not dying like was happening before vaccination."[216] By late August 2021 the Delta variant accounted for 99 percent of U.S. cases and was found to double the risk of severe illness and hospitalization for those not yet vaccinated.[217]

A September 2021 study found that having two doses of a COVID-19 vaccine halved the odds of long COVID.[218]

In November 2021, a study by the ECDC estimated that 470,000 lives over the age of 60 had been saved since the start of vaccination roll-out in the European region.[219]

On 10 December 2021, the UK Health Security Agency reported that early data indicated a 20- to 40-fold reduction in neutralizing activity for Omicron by sera from Pfizer 2-dose vaccinees relative to earlier strains. After a booster dose (usually with an mRNA vaccine),[220] vaccine effectiveness against symptomatic disease was at 70%–75%, and the effectiveness against severe disease was expected to be higher.[221]

According to early December 2021 CDC data, "unvaccinated adults were about 97 times more likely to die from COVID-19 than fully vaccinated people who had received boosters".[222]

A meta analysis looking into COVID-19 vaccine differences in immunosuppressed individuals found that people with a weakened immune system, are less able to produce neutralizing antibodies. For example, organ transplant recipients needing three vaccines to achieve seroconversion.[223] A study on the serologic response to mRNA vaccines among patients with lymphoma, leukemia and myeloma found that one-quarter of patients did not produce measurable antibodies, varying by cancer type.[224]

An April 2022 study suggested that natural immunity may offer similar protection from mild and severe cases of COVID-19 as the vaccines.[225][226]

Duration of immunity

As of 2021, data suggest fully vaccinated individuals and those previously infected with SARS-CoV-2 have a low risk of subsequent infection for at least six months.[227][228][229] Data are currently insufficient to determine an antibody titer threshold that indicates when an individual is protected from infection. Multiple studies show that antibody titers are associated with protection at the population level, but individual protection titers remain unknown. For some populations, such as the elderly and the immunocompromised, protection levels may be reduced after both vaccination and infection. Finally, current data suggest that the level of protection may not be the same for all variants of the virus.[227]

As new data continue to emerge,[230] recommendations will need to be updated periodically. As of December 2021, there are no authorized or approved tests that providers or the public can use to reliably determine if a person is protected from infection.[227]

As of March 2022, elderly residents' protection against severe illness, hospitalization and death in English care homes was high immediately after vaccination, but protection declined significantly in the months following vaccination. Protection among care home staff, who were younger, declined much more slowly. Regular boosters are recommended for older people and boosters every six months for care home residents appear reasonable.[231]

A December 2021 Qatari study found that the Pfizer–BioNTech COVID-19 vaccine was 81.5% effective at preventing infection in the first month after receiving the second dose, but that efficacy dropped to 12.8% within 6 months.[232][non-primary source needed]

The CDC recommends a fourth dose of the Pfizer mRNA vaccine as of March 2022, for "certain immunocompromised individuals and people over the age of 50".[233][234]

Immune evasion by variants

In contrast to other investigated prior variants, the SARS-CoV-2 Omicron variant[235][236][237][238][239] and its BA.4/5 subvariants[240] are evading immunity induced by vaccines, which may lead to breakthrough infections despite, even recent, vaccination. Nevertheless, current vaccines are thought to provide a level of protection against severe illness, hospitalizations, and deaths due to Omicron.[241]

Vaccine adjustments
As of June 2022, researchers, health organizations and regulators are discussing, investigating (including with preliminary laboratory studies and trials) and partly recommending COVID-19 vaccine boosters that mix the original vaccine formulation with Omicron-adjusted parts – such as spike proteins of a specific Omicron subvariant – to better prepare the immune system to recognize a wide variety of variants amid substantial and ongoing immune evasion by Omicron.[242]

Effectiveness against transmission

As of 2022, fully vaccinated individuals with breakthrough infections with SARS-CoV-2 delta (B.1.617.2) variant have peak viral load similar to unvaccinated cases and are able to transmit infection in household settings.[243]

Mix and match

According to studies, the combination of two different COVID-19 vaccines, also called cross vaccination or mix-and-match method, provides protection equivalent to that of mRNA vaccines – including protection against the Delta variant. Individuals who receive the combination of two different vaccines produce strong immune responses, with side effects no worse than those caused by standard regimens.[244][245]

Adverse events

For most people, the side effects, also called adverse effects, from COVID-19 vaccines are mild and can be managed at home.

All vaccines that are administered via intramuscular injection, including COVID‑19 vaccines, have side effects related to the mild trauma associated with the procedure and introduction of a foreign substance into the body.[246] These include soreness, redness, rash, and inflammation at the injection site. Other common side effects include fatigue, headache, myalgia (muscle pain), and arthralgia (joint pain), all of which generally resolve without medical treatment within a few days.[11][12] Also like any other vaccine, some people are allergic to one or more ingredients in COVID-19 vaccines. Typical side effects are stronger and more common in younger people and in subsequent doses, and up to 20% of people report a disruptive level of side effects after the second dose of an mRNA vaccine.[247] These side effects are less common or weaker in inactivated vaccines.[247]

COVID-19 vaccination is safe for people who are breastfeeding.[13] Temporary changes to the menstrual cycle in young women have been reported, although these changes are "small compared with natural variation and quickly reverse".[248] In one study, women who received both doses of a two-dose vaccine during the same menstrual cycle (an atypical situation) may see their next period begin a couple of days late, and they have about twice the usual risk of a clinically significant delay (about 10% of these women, compared to about 4% of unvaccinated women).[248] Cycle lengths return to normal after two menstrual cycles post-vaccination.[248] Women who received doses in separate cycles had approximately the same natural variation in cycle lengths as unvaccinated women.[248] Other temporary menstrual effects have been reported, such as heavier than normal menstrual bleeding after vaccination.[248]

Serious adverse events associated COVID‑19 vaccines are generally rare but of high interest to the public.[249] The official databases of reported adverse events include the World Health Organization's VigiBase, the United States Vaccine Adverse Events Reporting System (VAERS) and the United Kingdom's Yellow Card Scheme. Increased public awareness of these reporting systems and the extra reporting requirements under US FDA Emergency Use Authorization rules have resulted in an increased volume of reported adverse events.[250]

Rare serious effects include:

  • anaphylaxis, which is severe type of allergic reaction.[251] Anaphylaxis affects one person per 250,000 to 400,000 doses administered.[247][252]
  • blood clots (thrombosis).[251] These vaccine-induced immune thrombocytopenia and thrombosis are associated with vaccines using an adenovirus system (Janssen and Oxford-AstraZeneca).[251] These affect about one person per 100,000.[247]
  • myocarditis and pericarditis, or inflammation of the heart.[251] There is a rare risk of myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the membrane covering the heart) after the mRNA Covid-19 vaccines (Moderna Covid-19 vaccine or the Pfizer-BioNTech Covid-19 vaccine). The risk of myocarditis after Covid-19 vaccination is estimated to be 0.3 to 5 cases per 100,000 persons with the highest risk in young males.[253] In an Israeli nation-wide population based study (in which the Pfizer-BioNTech vaccine was exclusively given), the incidence rate of myocarditis was 54 cases per 2.5 million vaccine recipients, with an overall incidence rate of 2 cases per 100,000 persons, with the highest incidence seen in young males (aged 16 to 29) at 10 cases per 100,000 vaccine recipients. Of the cases of myocarditis seen, 76% were mild in severity, with only 1 case of cardiogenic shock (heart failure) and no deaths reported due to myocarditis.[254] Covid-19 vaccines may protect against myocarditis due to subsequent Covid-19 infection as the risk of myocarditis after Covid-19 infection was 50% less in those who were vaccinated compared to unvaccinated persons.[255] The risk of myocarditis and pericarditis is significantly higher (up to 11 times higher with respect to myocarditis) after Covid-19 infection as compared to Covid-19 vaccination, with the possible exception of younger men (less than 40 years old) who may have a higher risk of myocarditis after the second Moderna mRNA vaccine (an additional 97 cases of myocarditis per 1 million persons vaccinated).[255]
  • thrombotic thrombocytopenia and other autoimmune diseases, which have been reported as adverse events after COVID-19 vaccine.[256]

Because COVID-19 vaccines are relatively new, new claims about possible side effects are being made, and sometimes reports conflict.[257] For example, there are rare reports of subjective hearing changes, including tinnitus, after vaccination.[252][258][257]

The rate and type of side effects is also compared to the alternatives. For example, although vaccination may trigger some side effects, the effects experienced from an infection could be worse. Neurological side effects from getting COVID-19 are hundreds of times more likely than from vaccination.[259]

Society and culture


Note about table in this section: Number and percentage of people who have received at least one dose of a COVID‑19 vaccine (unless noted otherwise). May include vaccination of non-citizens, which can push totals beyond 100% of the local population. Table is updated daily by a bot.[note 2]

Updated December 5, 2022.
COVID-19 vaccine distribution by country[260]
Location Vaccinated[b] Percent[c]
World[d][e] 5,463,343,651 68.50%
China China[f] 1,304,631,000 91.50%
India India 1,027,062,119 72.47%
European Union European Union[g] 337,977,717 75.08%
United States United States[h] 267,346,533 80.52%
Indonesia Indonesia 203,715,848 73.94%
Brazil Brazil 188,077,016 87.35%
Bangladesh Bangladesh 149,128,228 87.11%
Pakistan Pakistan 139,628,133 59.21%
Japan Japan 104,409,189 84.23%
Mexico Mexico 99,071,001 77.70%
Vietnam Vietnam 90,156,999 91.82%
Russia Russia 87,235,723 60.28%
Philippines Philippines 78,196,194 67.67%
Iran Iran 65,103,298 73.52%
Germany Germany 64,823,644 77.75%
Nigeria Nigeria 63,982,167 29.28%
Turkey Turkey 57,941,051 67.89%
Thailand Thailand 57,005,497 79.62%
France France 54,610,278 80.53%
United Kingdom United Kingdom 53,806,963 79.97%
Egypt Egypt 53,646,548 48.33%
Italy Italy[i] 50,859,517 86.15%
South Korea South Korea 45,131,958 87.10%
Ethiopia Ethiopia 44,695,420 37.16%
Colombia Colombia 42,886,655 82.67%
Argentina Argentina 41,376,327 90.92%
Spain Spain 41,310,693 86.99%
Myanmar Myanmar 34,777,314 64.64%
Canada Canada 34,367,278 89.37%
Peru Peru 30,125,995 88.48%
Tanzania Tanzania 28,204,265 43.06%
Malaysia Malaysia 28,116,144 82.85%
Nepal Nepal 27,398,529 89.69%
Saudi Arabia Saudi Arabia 26,931,916 73.97%
Morocco Morocco 25,013,253 66.78%
Poland Poland 22,830,298 57.28%
South Africa South Africa 22,475,190 37.53%
Australia Australia 22,236,983 84.95%
Venezuela Venezuela 22,157,232 78.29%
Taiwan Taiwan 21,809,758 91.28%
Uzbekistan Uzbekistan 21,247,096 61.36%
Uganda Uganda 18,867,075 41.15%
Mozambique Mozambique 18,585,783 56.37%
Chile Chile 18,080,462 92.23%
Sri Lanka Sri Lanka 17,143,761 78.53%
Ukraine Ukraine 15,729,617 36.19%
Ecuador Ecuador 15,303,829 85.02%
Cambodia Cambodia 15,226,312 90.81%
Angola Angola 14,220,830 39.96%
Kenya Kenya 14,093,092 26.09%
Netherlands Netherlands 12,775,557 73.00%
Ivory Coast Ivory Coast 12,340,126 43.82%
Ghana Ghana 12,016,344 35.90%
Afghanistan Afghanistan 11,292,816 27.46%
Iraq Iraq 11,281,293 25.35%
Kazakhstan Kazakhstan 10,847,465 55.92%
Zambia Zambia 10,802,844 53.97%
Cuba Cuba 10,715,609 95.57%
Rwanda Rwanda 10,572,981 76.75%
United Arab Emirates United Arab Emirates 9,991,089 100.00%
Portugal Portugal 9,769,228 95.12%
Belgium Belgium 9,262,734 79.47%
Sudan Sudan 9,197,424 19.62%
Guatemala Guatemala 8,853,795 49.62%
Romania Romania 8,183,574 41.63%
Greece Greece 7,931,563 76.38%
Algeria Algeria 7,840,131 17.75%
Sweden Sweden 7,813,295 74.06%
Bolivia Bolivia 7,361,008 60.94%
Dominican Republic Dominican Republic 7,297,111 64.99%
Tunisia Tunisia 7,215,570 58.40%
Somalia Somalia 7,137,557 40.56%
Czech Republic Czech Republic 6,975,796 66.47%
Hong Kong Hong Kong 6,901,625 92.16%
Austria Austria 6,894,948 77.13%
Israel Israel 6,721,572 71.14%
Belarus Belarus 6,512,843 68.30%
Zimbabwe Zimbabwe 6,437,808 40.25%
Honduras Honduras 6,420,766 61.54%
Hungary Hungary 6,420,202 64.41%
Nicaragua Nicaragua 6,142,306 88.40%
Switzerland Switzerland 6,095,349 69.74%
Niger Niger 5,935,299 22.65%
Laos Laos 5,888,649 79.31%
Guinea Guinea 5,809,781 41.92%
Democratic Republic of the Congo Democratic Republic of the Congo 5,719,214 5.78%
Azerbaijan Azerbaijan 5,373,253 52.10%
Tajikistan Tajikistan 5,282,863 54.18%
Singapore Singapore 5,156,279 91.47%
Jordan Jordan 4,821,579 43.25%
Denmark Denmark 4,802,680 81.65%
El Salvador El Salvador 4,652,597 73.69%
Costa Rica Costa Rica 4,541,315 87.66%
Finland Finland 4,523,315 81.64%
Norway Norway 4,346,995 79.99%
New Zealand New Zealand 4,298,557 82.90%
Republic of Ireland Republic of Ireland 4,103,340 81.69%
Paraguay Paraguay 3,974,532 58.61%
Malawi Malawi 3,920,784 19.21%
Chad Chad 3,749,370 21.16%
Liberia Liberia 3,748,721 70.69%
Sierra Leone Sierra Leone 3,704,679 43.05%
Panama Panama 3,514,297 79.71%
Kuwait Kuwait 3,453,545 80.90%
Serbia Serbia 3,354,075 48.81%
Oman Oman 3,257,365 71.18%
Benin Benin 3,209,393 24.04%
Burkina Faso Burkina Faso 3,079,151 13.93%
Syria Syria 3,050,850 13.79%
Uruguay Uruguay 3,002,536 87.72%
Qatar Qatar 2,849,216 105.72%
Slovakia Slovakia 2,822,919 51.82%
Mali Mali 2,788,248 12.34%
Lebanon Lebanon 2,738,210 49.88%
Croatia Croatia 2,320,332 57.57%
Libya Libya 2,308,724 34.28%
Mongolia Mongolia 2,272,965 68.27%
Togo Togo 2,239,907 25.31%
South Sudan South Sudan 2,153,336 19.73%
Bulgaria Bulgaria 2,104,168 31.03%
Mauritania Mauritania 2,055,002 43.39%
State of Palestine Palestine 2,012,767 38.34%
Lithuania Lithuania 1,956,204 71.13%
Senegal Senegal 1,910,386 11.03%
Madagascar Madagascar 1,885,035 6.37%
Central African Republic Central African Republic 1,748,700 31.34%
Botswana Botswana 1,679,676 63.86%
Georgia (country) Georgia 1,654,504 44.03%
Cameroon Cameroon 1,651,151 5.92%
Kyrgyzstan Kyrgyzstan 1,629,071 24.57%
Latvia Latvia 1,346,184 71.84%
Albania Albania 1,340,678 47.17%
Slovenia Slovenia 1,265,802 59.72%
Bahrain Bahrain 1,241,104 84.30%
Armenia Armenia 1,128,072 38.01%
Mauritius Mauritius 1,123,773 86.48%
Moldova Moldova 1,103,268 33.71%
Yemen Yemen 1,003,208 2.98%
Lesotho Lesotho 995,466 43.17%
Bosnia and Herzegovina Bosnia and Herzegovina 943,394 28.91%
Kosovo Kosovo 906,559 50.87%
East Timor Timor-Leste 872,617 65.06%
Estonia Estonia 868,225 65.47%
North Macedonia North Macedonia 854,392 40.81%
Jamaica Jamaica 835,930 29.57%
Trinidad and Tobago Trinidad and Tobago 753,588 49.39%
Fiji Fiji 711,256 76.50%
Bhutan Bhutan 699,116 89.35%
Republic of the Congo Republic of the Congo 695,760 11.92%
Cyprus Cyprus 669,939 74.77%
Macau Macau 652,674 93.89%
Guinea-Bissau Guinea-Bissau 640,393 31.08%
Namibia Namibia 598,222 23.30%
The Gambia Gambia 548,701 20.28%
Guyana Guyana 493,404 61.01%
Eswatini Eswatini 492,300 41.29%
Luxembourg Luxembourg 481,858 74.41%
Malta Malta 478,442 89.71%
Brunei Brunei 450,404 100.31%
Comoros Comoros 438,825 53.41%
Maldives Maldives 399,146 76.20%
Haiti Haiti 398,517 3.44%
Papua New Guinea Papua New Guinea 364,090 3.59%
Cape Verde Cabo Verde 356,734 60.68%
Solomon Islands Solomon Islands 343,821 47.47%
Gabon Gabon 310,842 13.01%
Iceland Iceland 309,770 84.00%
Djibouti Djibouti 299,297 26.70%
Montenegro Montenegro 292,783 46.63%
Northern Cyprus Northern Cyprus 284,357 74.39%
Equatorial Guinea Equatorial Guinea 270,109 16.53%
Suriname Suriname 267,820 45.26%
Belize Belize 251,773 62.12%
New Caledonia New Caledonia 191,660 66.10%
Samoa Samoa 191,130 85.94%
French Polynesia French Polynesia 190,765 62.28%
The Bahamas Bahamas 174,147 42.48%
Barbados Barbados 163,777 58.15%
Vanuatu Vanuatu 144,824 44.32%
São Tomé and Príncipe Sao Tome and Principe 127,423 56.04%
Curaçao Curaçao 108,601 56.81%
Kiribati Kiribati 96,184 73.29%
Tonga Tonga 91,949 86.04%
Aruba Aruba 90,092 84.63%
Seychelles Seychelles 85,720 80.01%
Jersey Jersey 84,294 76.08%
Isle of Man Isle of Man 69,560 81.44%
Antigua and Barbuda Antigua and Barbuda 64,290 68.97%
Cayman Islands Cayman Islands 61,818 89.95%
Saint Lucia Saint Lucia 60,140 33.43%
Andorra Andorra 57,901 72.52%
Guernsey Guernsey 54,222 85.62%
Bermuda Bermuda 48,554 75.65%
Grenada Grenada 44,180 35.21%
Gibraltar Gibraltar 42,074 124.88%
Faroe Islands Faroe Islands 41,715 85.04%
Greenland Greenland 41,243 72.52%
Saint Vincent and the Grenadines Saint Vincent and the Grenadines 37,332 35.91%
Saint Kitts and Nevis Saint Kitts and Nevis 33,794 70.99%
Dominica Dominica 32,995 45.57%
Turks and Caicos Islands Turks and Caicos Islands 32,338 71.68%
Turkmenistan Turkmenistan 32,240 0.53%
Sint Maarten Sint Maarten 29,788 67.41%
Liechtenstein Liechtenstein 26,764 68.01%
Monaco Monaco 26,672 67.49%
San Marino San Marino 26,357 77.50%
Burundi Burundi 26,110 0.20%
British Virgin Islands British Virgin Islands 19,466 62.55%
Caribbean Netherlands Caribbean Netherlands 19,109 72.26%
Cook Islands Cook Islands 15,084 88.56%
Nauru Nauru 11,522 90.79%
Anguilla Anguilla 10,852 68.35%
Wallis and Futuna Wallis and Futuna 7,136 61.54%
Tuvalu Tuvalu 6,368 53.40%
Saint Helena, Ascension and Tristan da Cunha Saint Helena, Ascension and Tristan da Cunha 4,361 71.83%
Falkland Islands Falkland Islands 2,632 75.57%
Montserrat Montserrat 2,104 47.63%
Niue Niue 1,650 102.23%
Tokelau Tokelau 1,494 78.92%
Pitcairn Islands Pitcairn Islands 47 100.00%
North Korea North Korea 0 0.00%
  1. ^ The Oxford–AstraZeneca COVID‑19 vaccine is codenamed AZD1222,[165] and later supplied under brand names, including Vaxzevria[166] and Covishield.[167][168]
  2. ^ Number of people who have received at least one dose of a COVID-19 vaccine (unless noted otherwise).
  3. ^ Percentage of population that has received at least one dose of a COVID-19 vaccine. May include vaccination of non-citizens, which can push totals beyond 100% of the local population.
  4. ^ Countries which do not report data for a column are not included in that column's world total.
  5. ^ Vaccination Note: Countries which do not report the number of people who have received at least one dose are not included in the world total.
  6. ^ Does not include special administrative regions (Hong Kong and Macau) or Taiwan.
  7. ^ Data on member states of the European Union are individually listed, but are also summed here for convenience. They are not double-counted in world totals.
  8. ^ Vaccination Note: Includes Freely Associated States
  9. ^ Vaccination Note: Includes Vatican City

As of 5 December 2022, 12.7 billion COVID-19 vaccine doses have been administered worldwide, with 67.9 percent of the global population having received at least one dose. While 4.19 million vaccines were then being administered daily, only 22.3 percent of people in low-income countries had received at least a first vaccine by September 2022, according to official reports from national health agencies, which are collated by Our World in Data.[261]

During a pandemic on the rapid timeline and scale of COVID-19 cases in 2020, international organizations like the World Health Organization (WHO) and Coalition for Epidemic Preparedness Innovations (CEPI), vaccine developers, governments, and industry evaluated the distribution of the eventual vaccine(s).[262] Individual countries producing a vaccine may be persuaded to favor the highest bidder for manufacturing or provide first-service to their own country.[263][264][265][266][excessive citations] Experts emphasize that licensed vaccines should be available and affordable for people at the frontline of healthcare and having the most need.[263][264][266]

In April 2020, it was reported that the UK agreed to work with 20 other countries and global organizations including France, Germany, and Italy to find a vaccine and to share the results and that UK citizens would not get preferential access to any new COVID‑19 vaccines developed by taxpayer-funded UK universities.[267] Several companies planned to initially manufacture a vaccine at artificially low pricing, then increase prices for profitability later if annual vaccinations are needed and as countries build stock for future needs.[266]

An April 2020 CEPI report stated: "Strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies, and governments will be needed to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas, particularly low-resource regions."[268] The World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) are developing financial resources and guidelines for the global deployment of several safe, effective COVID‑19 vaccines, recognizing the need are different across countries and population segments.[262][269][270][271][excessive citations] For example, successful COVID‑19 vaccines would be allocated early to healthcare personnel and populations at greatest risk of severe illness and death from COVID‑19 infection, such as the elderly or densely-populated impoverished people.[272][273]

The World Health Organization (WHO) had set out the target to vaccinate 40% of the population of all countries by the end of 2021 and 70% by mid-2022,[274] but many countries missed the 40% target at the end of 2021.[275][276]


Countries have extremely unequal access to the COVID-19 vaccine. Vaccine equity has not been achieved, or even approximated. The inequity has harmed both countries with poor access and countries with good access.[17][18][277]

Nations pledged to buy doses of the COVID‑19 vaccine before the doses were available. Though high-income nations represent only 14% of the global population, as of 15 November 2020, they had contracted to buy 51% of all pre-sold doses. Some high-income nations bought more doses than would be necessary to vaccinate their entire populations.[16]

Production of Sputnik V vaccine in Brazil, January 2021.
An elderly man receiving second dose of CoronaVac vaccine in Brazil, April 2021.
Covid vaccination for children aged 12–14 in Bhopal, India

In January 2021, WHO Director-General Tedros Adhanom Ghebreyesus warned of problems with equitable distribution: "More than 39 million doses of vaccine have now been administered in at least 49 higher-income countries. Just 25 doses have been given in one lowest-income country. Not 25 million; not 25 thousand; just 25."[278]

In March 2021, it was revealed the US attempted to convince Brazil not to purchase the Sputnik V COVID‑19 vaccine, fearing "Russian influence" in Latin America.[279] Some nations involved in long-standing territorial disputes have reportedly had their access to vaccines blocked by competing nations; Palestine has accused Israel of blocking vaccine delivery to Gaza, while Taiwan has suggested that China has hampered its efforts to procure vaccine doses.[280][281][282]

A single dose of the COVID‑19 vaccine by AstraZeneca would cost 47 Egyptian pounds (EGP), and the authorities are selling it between 100 and 200 EGP. A report by Carnegie Endowment for International Peace cited the poverty rate in Egypt as around 29.7 percent, which constitutes approximately 30.5 million people, and claimed that about 15 million of the Egyptians would be unable to gain access to the luxury of vaccination. A human rights lawyer, Khaled Ali, launched a lawsuit against the government, forcing them to provide vaccination free of cost to all members of the public.[283]

According to immunologist Dr. Anthony Fauci, mutant strains of the virus and limited vaccine distribution pose continuing risks and he said: "we have to get the entire world vaccinated, not just our own country."[284] Edward Bergmark and Arick Wierson are calling for a global vaccination effort and wrote that the wealthier nations' "me-first" mentality could ultimately backfire because the spread of the virus in poorer countries would lead to more variants, against which the vaccines could be less effective.[285]

In March 2021, the United States, Britain, European Union member states and some other members of the World Trade Organization (WTO) blocked a push by more than eighty developing countries to waive COVID‑19 vaccine patent rights in an effort to boost production of vaccines for poor nations.[286] On 5 May 2021, the US government under President Joe Biden announced that it supports waiving intellectual property protections for COVID‑19 vaccines.[287] The Members of the European Parliament have backed a motion demanding the temporary lifting of intellectual properties rights for COVID‑19 vaccines.[288]

COVID‑19 mass vaccination queue in Finland, June 2021.
A drive-through COVID‑19 vaccination center in Iran, August 2021.

In a meeting in April 2021, the World Health Organization's emergency committee addressed concerns of persistent inequity in the global vaccine distribution.[289] Although 9 percent of the world's population lives in the 29 poorest countries, these countries had received only 0.3% of all vaccines administered as of May 2021.[290] In March 2021, Brazilian journalism agency Agência Pública reported that the country vaccinated about twice as many people who declare themselves white than black and noted that mortality from COVID‑19 is higher in the black population.[291]

In May 2021, UNICEF made an urgent appeal to industrialized nations to pool their excess COVID‑19 vaccine capacity to make up for a 125-million-dose gap in the COVAX program. The program mostly relied on the Oxford–AstraZeneca COVID‑19 vaccine produced by Serum Institute of India, which faced serious supply problems due to increased domestic vaccine needs in India from March to June 2021. Only a limited amount of vaccines can be distributed efficiently, and the shortfall of vaccines in South America and parts of Asia are due to a lack of expedient donations by richer nations. International aid organizations have pointed at Nepal, Sri Lanka, and Maldives as well as Argentina and Brazil, and some parts of the Caribbean as problem areas, where vaccines are in short supply. In mid-May 2021, UNICEF was also critical of the fact that most proposed donations of Moderna and Pfizer vaccines were not slated for delivery until the second half of 2021, or early in 2022.[292]

In July 2021, the heads of the World Bank Group, the International Monetary Fund, the World Health Organization, and the World Trade Organization said in a joint statement: "As many countries are struggling with new variants and a third wave of COVID‑19 infections, accelerating access to vaccines becomes even more critical to ending the pandemic everywhere and achieving broad-based growth. We are deeply concerned about the limited vaccines, therapeutics, diagnostics, and support for deliveries available to developing countries."[293][294] In July 2021, The BMJ reported that countries have thrown out over 250,000 vaccine doses as supply exceeded demand and strict laws prevented the sharing of vaccines.[295] A survey by The New York Times found that over a million doses of vaccine had been thrown away in ten U.S. states because federal regulations prohibit recalling them, preventing their redistribution abroad.[296] Furthermore, doses donated close to expiration often cannot be administered quickly enough by recipient countries and end up having to be discarded.[297] To help overcome this problem, the Prime Minister of India, Narendra Modi announced that they would make their digital vaccination management platform CoWIN open to the global community. He also announced that India would also release the source code for contact tracing app Aarogya Setu for developers around the world. Around 142 countries including Afghanistan, Bangladesh, Bhutan, Maldives, Guyana, Antigua & Barbuda, St. Kitts & Nevis and Zambia expressed their interest in the application for COVID management.[298][299]

Amnesty International and Oxfam International have criticized the support of vaccine monopolies by the governments of producing countries, noting that this is dramatically increasing the dose price by five times and often much more, creating an economic barrier to access for poor countries.[300][301] Médecins Sans Frontières (Doctors without Borders) has also criticized vaccine monopolies and repeatedly called from their suspension, supporting the TRIPS Waiver. The waiver was first proposed in October 2020, and has support from most countries, but delayed by opposition from EU (especially Germany - major EU countries such as France, Italy and Spain support the exemption),[302] UK, Norway, and Switzerland, among others. MSF called for a Day of Action in September 2021 to put pressure on the WTO Minister's meeting in November, which was expected to discuss the TRIPS IP waiver.[303][304][305]

Inside of a vaccination center in Brussels, Belgium, February 2021.

In August 2021, to reduce unequal distribution between rich and poor countries, the WHO called for a moratorium on a booster dose at least until the end of September. However, in August, the United States government announced plans to offer booster doses eight months after the initial course to the general population, starting with priority groups. Before the announcement, the WHO harshly criticized this type of decision, citing the lack of evidence for the need for boosters, except for patients with specific conditions. At this time, vaccine coverage of at least one dose was 58% in high-income countries and only 1.3% in low-income countries, and 1.14 million Americans already received an unauthorized booster dose. US officials argued that waning efficacy against mild and moderate disease might indicate reduced protection against severe disease in the coming months. Israel, France, Germany, and the United Kingdom have also started planning boosters for specific groups.[306][307][308] In September 2021, more than 140 former world leaders, and Nobel laureates, including former President of France François Hollande, former Prime Minister of the United Kingdom Gordon Brown, former Prime Minister of New Zealand Helen Clark, and Professor Joseph Stiglitz, called on the candidates to be the next German chancellor to declare themselves in favour of waiving intellectual property rules for COVID‑19 vaccines and transferring vaccine technologies.[309] In November 2021, nursing unions in 28 countries have filed a formal appeal with the United Nations over the refusal of the UK, EU, Norway, Switzerland, and Singapore to temporarily waive patents for Covid vaccines.[310]

During his first international trip, President of Peru Pedro Castillo spoke at the seventy-sixth session of the United Nations General Assembly on 21 September 2021, proposing the creation of an international treaty signed by world leaders and pharmaceutical companies to guarantee universal vaccine access, arguing "The battle against the pandemic has shown us the failure of the international community to cooperate under the principle of solidarity".[311][312]

Optimizing the societal benefit of vaccination may benefit from a strategy that is tailored to the state of the pandemic, the demographics of a country, the age of the recipients, the availability of vaccines, and the individual risk for severe disease: In the UK, the interval between prime and boost dose was extended to vaccinate as many persons as early as possible,[313] many countries are starting to give an additional booster shot to the immunosuppressed[314][315] and the elderly,[316] and research predicts an additional benefit of personalizing vaccine dose in the setting of limited vaccine availability when a wave of virus Variants of Concern hits a country.[317]

Despite the extremely rapid development of effective mRNA and viral vector vaccines, vaccine equity has not been achieved.[17] The World Health Organization called for 70 per cent of the global population to be vaccinated by mid-2022, but as of March 2022 it was estimated that only one per cent of the 10 billion doses given worldwide had been administered in low-income countries.[318] An additional 6 billion vaccinations may be needed to fill vaccine access gaps, particularly in developing countries. Given the projected availability of the newer vaccines, the development and use of whole inactivated virus (WIV) and protein-based vaccines are also recommended. Organizations such as the Developing Countries Vaccine Manufacturers Network could help to support the production of such vaccines in developing countries, with lower production costs and greater ease of deployment.[17][319]

While vaccines substantially reduce the probability and severity of infection, it is still possible for fully vaccinated people to contract and spread COVID‑19.[320] Public health agencies have recommended that vaccinated people continue using preventive measures (wear face masks, social distance, wash hands) to avoid infecting others, especially vulnerable people, particularly in areas with high community spread. Governments have indicated that such recommendations will be reduced as vaccination rates increase and community spread declines.[321]


Moreover, an unequal distribution of vaccines will deepen inequality and exaggerate the gap between rich and poor and will reverse decades of hard-won progress on human development.
— United Nations, COVID vaccines: Widening inequality and millions vulnerable[322]

Vaccine inequity damages the global economy, disrupting the global supply chain.[277] Most vaccines were being reserved for wealthy countries, as of September 2021,[322] some of which have more vaccine than is needed to fully vaccinate their populations.[16] When people, undervaccinated, needlessly die, experience disability, and live under lockdown restrictions, they cannot supply the same goods and services. This harms the economies of undervaccinated and overvaccinated countries alike. Since rich countries have larger economies, rich countries may lose more money to vaccine inequity than poor ones,[277] though the poor ones will lose a higher percentage of GDP and experience longer-term effects.[323] High-income countries would profit an estimated US$4.80 for every $1 spent on giving vaccines to lower-income countries.[277]

The International Monetary Fund sees the vaccine divide between rich and poor nations as a serious obstacle to a global economic recovery.[324] Vaccine inequity disproportionately affects refuge-providing states, as they tend to be poorer, and refugees and displaced people are economically more vulnerable even within those low-income states, so they have suffered more economically from vaccine inequity.[325][17]


Several governments agreed to shield pharmaceutical companies like Pfizer and Moderna from negligence claims related to COVID‑19 vaccines (and treatments), as in previous pandemics, when governments also took on liability for such claims.

In the US, these liability shields took effect on 4 February 2020, when the US Secretary of Health and Human Services Alex Azar published a notice of declaration under the Public Readiness and Emergency Preparedness Act (PREP Act) for medical countermeasures against COVID‑19, covering "any vaccine, used to treat, diagnose, cure, prevent, or mitigate COVID‑19, or the transmission of SARS-CoV-2 or a virus mutating therefrom". The declaration precludes "liability claims alleging negligence by a manufacturer in creating a vaccine, or negligence by a health care provider in prescribing the wrong dose, absent willful misconduct." In other words, absent "willful misconduct", these companies can not be sued for money damages for any injuries that occur between 2020 and 2024 from the administration of vaccines and treatments related to COVID‑19.[326] The declaration is effective in the United States through 1 October 2024.[326]

In December 2020, the UK government granted Pfizer legal indemnity for its COVID‑19 vaccine.[327]

In the European Union, the COVID‑19 vaccines were granted a conditional marketing authorization which does not exempt manufacturers from civil and administrative liability claims.[328] The EU conditional marketing authorizations were changed to standard authorizations in September 2022.[329] While the purchasing contracts with vaccine manufacturers remain secret, they do not contain liability exemptions even for side-effects not known at the time of licensure.[330]

The Bureau of Investigative Journalism, a nonprofit news organization, reported in an investigation that unnamed officials in some countries, such as Argentina and Brazil, said that Pfizer demanded guarantees against costs of legal cases due to adverse effects in the form of liability waivers and sovereign assets such as federal bank reserves, embassy buildings or military bases, going beyond the expected from other countries such as the US.[331] During the pandemic parliamentary inquiry in Brazil, Pfizer's representative said that its terms for Brazil are the same as for all other countries with which it has signed deals.[332]


In June 2021, a report revealed that the UB-612 vaccine, developed by the US-based COVAXX, was a for-profit venture initiated by the Blackwater founder Erik Prince. In a series of text messages to Paul Behrends, the close associate recruited for the COVAXX project, Prince described the profit-making possibilities in selling the COVID‑19 vaccines. COVAXX provided no data from the clinical trials on safety or efficacy it conducted in Taiwan. The responsibility of creating distribution networks was assigned to an Abu Dhabi-based entity, which was mentioned as "Windward Capital" on the COVAXX letterhead but was actually Windward Holdings. The firm's sole shareholder, which handled "professional, scientific and technical activities", was Erik Prince. In March 2021, COVAXX raised $1.35 billion in a private placement.[333]

Misinformation and hesitancy

A protest against COVID-19 vaccination in London, United Kingdom
Anti-vaccination activists and other people in many countries have spread a variety of unfounded conspiracy theories and other misinformation about COVID-19 vaccines based on misunderstood or misrepresented science, religion, exaggerated claims about side effects, a story about COVID-19 being spread by 5G, misrepresentations about how the immune system works and when and how COVID-19 vaccines are made, and other false or distorted information. This misinformation has proliferated and may have made many people averse to vaccination.[334] This has led to governments and private organizations around the world introducing measures to incentivize/coerce vaccination, such as lotteries,[335] mandates[336] and free entry to events,[337] which has in turn led to further misinformation about the legality and effect of these measures themselves.[338]

See also

Explanatory notes

  1. ^ Our World in Data (OWID) vaccination maps. Click on the download tab to download the map. The table tab has a table of the exact data by country. The source tab says the data is from verifiable public official sources Archived 21 December 2021 at the Wayback Machine collated by Our World in Data. The map at the source is interactive and provides more detail. Run your cursor over the color bar legend to see the countries that apply to that point in the legend. There is an OWID vaccination info FAQ Archived 10 March 2021 at the Wayback Machine.
  2. ^ The table data is automatically updated daily by a bot; see Template:COVID-19 data for more information. Scroll down past the table to find the documentation and the main reference. See also: Category:Automatically updated COVID-19 pandemic table templates.


  1. ^ Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790. PMID 33341119.
  2. ^ Subbarao K (July 2021). "The success of SARS-CoV-2 vaccines and challenges ahead". Cell Host & Microbe. 29 (7): 1111–1123. doi:10.1016/j.chom.2021.06.016. PMC 8279572. PMID 34265245.
  3. ^ Padilla TB (24 February 2021). "No one is safe unless everyone is safe". BusinessWorld. Archived from the original on 23 February 2021. Retrieved 24 February 2021.
  4. ^ a b c d Rogers K (11 May 2022). "COVID-19 vaccine". Encyclopædia Britannica. Archived from the original on 12 June 2022. Retrieved 12 June 2022.
  5. ^ "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 18 December 2020. Archived from the original on 2 May 2021. Retrieved 5 July 2022.
  6. ^ "EMA recommends first COVID-19 vaccine for authorisation in the EU". European Medicines Agency (EMA) (Press release). 21 December 2020. Archived from the original on 30 January 2021. Retrieved 21 December 2020.
  7. ^ Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R (December 2021). "How COVID vaccines shaped 2021 in eight powerful charts". Nature. 600 (7890): 580–583. Bibcode:2021Natur.600..580M. doi:10.1038/d41586-021-03686-x. PMID 34916666. S2CID 245262732.
  8. ^ Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (June 2022). "Global impact of the first year of COVID-19 vaccination: a mathematical modelling study". The Lancet Infectious Diseases. 22 (9): 1293–1302. doi:10.1016/s1473-3099(22)00320-6. PMC 9225255. PMID 35753318.
  9. ^ "COVID-19 vaccines saved nearly 20 million lives in a year, study says". CBS News. 24 June 2022. Archived from the original on 29 June 2022. Retrieved 27 June 2022.
  10. ^ Beaumont P (18 November 2020). "Covid-19 vaccine: who are countries prioritising for first doses?". The Guardian. ISSN 0261-3077. Archived from the original on 18 January 2021. Retrieved 26 December 2020.
  11. ^ a b Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 (Report). World Health Organization (WHO). February 2021. hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 24 July 2021.
  12. ^ a b "Background document on the mRNA-1273 vaccine (Moderna) against COVID-19". World Health Organization (WHO). Archived from the original on 26 January 2022. Retrieved 23 January 2022.
  13. ^ a b "Pregnancy, breastfeeding, fertility and coronavirus (COVID-19) vaccination". NHS. 5 October 2022.
  14. ^ Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (March 2020). "Coronavirus (COVID-19) Vaccinations – Statistics and Research". Our World in Data. Archived from the original on 10 March 2021. Retrieved 7 February 2021.
  15. ^ Mullard A (November 2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811.
  16. ^ a b c So AD, Woo J (December 2020). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". BMJ. 371: m4750. doi:10.1136/bmj.m4750. PMC 7735431. PMID 33323376.
  17. ^ a b c d e Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
  18. ^ a b Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
  19. ^ "COVID-19 Bivalent Vaccine Boosters". U.S. Food and Drug Administration (FDA). 27 September 2022. Retrieved 8 October 2022.
  20. ^ a b c Gates B (30 April 2020). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.
  21. ^ Cavanagh D (December 2003). "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus". Avian Pathology. 32 (6): 567–582. doi:10.1080/03079450310001621198. PMC 7154303. PMID 14676007.
  22. ^ Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. (December 2003). "Effects of a SARS-associated coronavirus vaccine in monkeys". Lancet. 362 (9399): 1895–1896. doi:10.1016/S0140-6736(03)14962-8. PMC 7112457. PMID 14667748.
  23. ^ Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, et al. (October 2014). "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice". Vaccine. 32 (45): 5975–5982. doi:10.1016/j.vaccine.2014.08.058. PMC 7115510. PMID 25192975.
  24. ^ Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, et al. (February 2005). "Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice". The Journal of Infectious Diseases. 191 (4): 507–514. doi:10.1086/427242. PMC 7110081. PMID 15655773.
  25. ^ Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, et al. (September 2005). "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins". Journal of Virological Methods. 128 (1–2): 21–28. doi:10.1016/j.jviromet.2005.03.021. PMC 7112802. PMID 15885812.
  26. ^ Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, et al. (March 2006). "Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters". The Journal of Infectious Diseases. 193 (5): 685–692. doi:10.1086/500143. PMC 7109703. PMID 16453264.
  27. ^ a b Jiang S, Lu L, Du L (January 2013). "Development of SARS vaccines and therapeutics is still needed". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997. PMID 32201503.
  28. ^ "SARS (severe acute respiratory syndrome)". National Health Service. 5 March 2020. Archived from the original on 9 March 2020. Retrieved 31 January 2020.
  29. ^ Shehata MM, Gomaa MR, Ali MA, Kayali G (June 2016). "Middle East respiratory syndrome coronavirus: a comprehensive review". Frontiers of Medicine. 10 (2): 120–136. doi:10.1007/s11684-016-0430-6. PMC 7089261. PMID 26791756.
  30. ^ Butler D (October 2012). "SARS veterans tackle coronavirus". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020a. PMID 23038444.
  31. ^ Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. (September 2019). "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet. Infectious Diseases. 19 (9): 1013–1022. doi:10.1016/S1473-3099(19)30266-X. PMC 7185789. PMID 31351922.
  32. ^ Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019). "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781. PMC 6688523. PMID 31428074.
  33. ^ a b c Loftus P, Hopkins JS, Pancevski B (17 November 2020). "Moderna and Pfizer Are Reinventing Vaccines, Starting With Covid". The Wall Street Journal. Archived from the original on 6 November 2021. Retrieved 4 October 2021.
  34. ^ Sharma O, Sultan AA, Ding H, Triggle CR (14 October 2020). "A Review of the Progress and Challenges of Developing a Vaccine for COVID-19". Frontiers in Immunology. 11: 585354. doi:10.3389/fimmu.2020.585354. PMC 7591699. PMID 33163000.
  35. ^ Bok K, Sitar S, Graham BS, Mascola JR (August 2021). "Accelerated COVID-19 vaccine development: milestones, lessons, and prospects". Immunity. 54 (8): 1636–1651. doi:10.1016/j.immuni.2021.07.017. PMC 8328682. PMID 34348117.
  36. ^ Lewis T. "The New COVID Booster Shot Could Save Your Life; Get One Now, FDA Expert Says". Scientific American. Retrieved 8 November 2022.
  37. ^ Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. (August 2021). "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses". Nature. 596 (7870): 109–113. Bibcode:2021Natur.596..109T. doi:10.1038/s41586-021-03738-2. PMC 8935394. PMID 34182569.
  38. ^ "Pfizer and Moderna Vaccines Likely to Produce Lasting Immunity, Study Finds". The New York Times. 28 June 2021. Archived from the original on 28 June 2021. Retrieved 23 January 2022.
  39. ^ Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, et al. (2020). "Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines". Frontiers in Immunology. 11: 579250. doi:10.3389/fimmu.2020.579250. PMC 7566192. PMID 33123165.
  40. ^ a b c d e f g Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
  41. ^ a b "COVID-19 vaccine tracker (Refresh URL to update)". London School of Hygiene & Tropical Medicine. 12 July 2021. Archived from the original on 11 October 2020. Retrieved 10 March 2021.
  42. ^ Arbeitman CR, Rojas P, Ojeda-May P, Garcia ME (September 2021). "The SARS-CoV-2 spike protein is vulnerable to moderate electric fields". Nature Communications. 12 (1): 5407. arXiv:2103.12733. Bibcode:2021NatCo..12.5407A. doi:10.1038/s41467-021-25478-7. PMC 8437970. PMID 34518528.
  43. ^ a b Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. (June 2020). "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals". Cell. 181 (7): 1489–1501.e15. doi:10.1016/j.cell.2020.05.015. PMC 7237901. PMID 32473127.
  44. ^ Dutta NK, Mazumdar K, Gordy JT (June 2020). Dutch RE (ed.). "The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development". Journal of Virology. 94 (13). doi:10.1128/JVI.00647-20. PMC 7307180. PMID 32546606.
  45. ^ Nikolaidis M, Markoulatos P, Van de Peer Y, Oliver SG, Amoutzias GD (October 2021). Hepp C (ed.). "The neighborhood of the Spike gene is a hotspot for modular intertypic homologous and non-homologous recombination in Coronavirus genomes". Molecular Biology and Evolution. 39: msab292. doi:10.1093/molbev/msab292. PMC 8549283. PMID 34638137.
  46. ^ Amoutzias GD, Nikolaidis M, Tryfonopoulou E, Chlichlia K, Markoulatos P, Oliver SG (January 2022). "The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2". Viruses. 14 (1): 78. doi:10.3390/v14010078. PMC 8778387. PMID 35062282.
  47. ^ a b c d Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. PMID 32273591.
  48. ^ a b c Diamond MS, Pierson TC (May 2020). "The Challenges of Vaccine Development against a New Virus during a Pandemic". Cell Host & Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
  49. ^ Cross R (29 September 2020). "The tiny tweak behind COVID-19 vaccines". Chemical & Engineering News. Vol. 98, no. 38. Archived from the original on 16 February 2021. Retrieved 15 April 2021.
  50. ^ Krammer F (October 2020). "SARS-CoV-2 vaccines in development". Nature. 586 (7830): 516–527. Bibcode:2020Natur.586..516K. doi:10.1038/s41586-020-2798-3. PMID 32967006. S2CID 221887746.
  51. ^ Park KS, Sun X, Aikins ME, Moon JJ (February 2021). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews. 169: 137–151. doi:10.1016/j.addr.2020.12.008. ISSN 0169-409X. PMC 7744276. PMID 33340620.
  52. ^ Kowalski PS, Rudra A, Miao L, Anderson DG (April 2019). "Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery". Molecular Therapy. 27 (4): 710–728. doi:10.1016/j.ymthe.2019.02.012. PMC 6453548. PMID 30846391.
  53. ^ Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). "Three decades of messenger RNA vaccine development". Nano Today. 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. S2CID 202221207. Archived from the original on 9 October 2021. Retrieved 17 January 2021.
  54. ^ "COVID-19 ACIP Vaccine Recommendations". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 3 November 2021. Retrieved 18 February 2021.
  55. ^ "Safe COVID-19 vaccines for Europeans". European Commission. Archived from the original on 4 November 2021. Retrieved 19 February 2021.
  56. ^ "Regulatory Decision Summary – Pfizer–BioNTech COVID-19 Vaccine". Health Canada, Government of Canada. 9 December 2020. Archived from the original on 30 January 2021. Retrieved 9 December 2020.
  57. ^ "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  58. ^ "A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.
  59. ^ "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  60. ^ Palca J (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  61. ^ "CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60". CureVac (Press release). 30 June 2021. Archived from the original on 12 October 2021. Retrieved 2 July 2021.
  62. ^ a b c Moghimi SM (March 2021). "Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines". Molecular Therapy. 29 (3): 898–900. doi:10.1016/j.ymthe.2021.01.030. PMC 7862013. PMID 33571463.
  63. ^ a b "What are viral vector-based vaccines and how could they be used against COVID-19?". Gavi, the Vaccine Alliance (GAVI). 2020. Archived from the original on 11 November 2021. Retrieved 26 January 2021.
  64. ^ "Understanding Viral Vector COVID-19 Vaccines". U.S. Centers for Disease Control and Prevention (CDC). 13 April 2021. Archived from the original on 13 November 2021. Retrieved 19 April 2021.
  65. ^ "Investigating a Vaccine Against COVID-19". 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  66. ^ "A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.
  67. ^ O'Reilly P (May 2020). "A Phase III study to investigate a vaccine against COVID-19". ISRCTN Registry. doi:10.1186/ISRCTN89951424. ISRCTN89951424.
  68. ^ Corum J, Carl Z (8 January 2021). "How Gamaleya's Vaccine Works". The New York Times. Archived from the original on 20 April 2021. Retrieved 27 January 2021.
  69. ^ "A Study of Ad26.COV2.S in Adults". 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.
  70. ^ "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". US National Library of Medicine. Archived from the original on 26 September 2020.
  71. ^ Johnson C, McGinley L. "Johnson & Johnson seeks emergency FDA authorization for single-shot coronavirus vaccine". The Washington Post. Archived from the original on 5 February 2021. Retrieved 10 February 2021.
  72. ^ "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective". Fortune. Archived from the original on 8 August 2021. Retrieved 28 February 2021.
  73. ^ Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. (August 2020). "A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge". Nat Commun. 11 (1): 4081. Bibcode:2020NatCo..11.4081W. doi:10.1038/s41467-020-17972-1. PMC 7427994. PMID 32796842.
  74. ^ "Single dose vaccine, Sputnik Light, authorized for use in Russia". Sputnik V (Press release). Archived from the original on 14 November 2021. Retrieved 12 August 2021.
  75. ^ "Introducing a new member of the Sputnik family – a single dose Sputnik Light!". Twitter. Archived from the original on 18 October 2021. Retrieved 12 August 2021.
  76. ^ Petrovsky N, Aguilar JC (October 2004). "Vaccine adjuvants: current state and future trends". Immunology and Cell Biology. 82 (5): 488–496. doi:10.1111/j.0818-9641.2004.01272.x. PMID 15479434. S2CID 154670.
  77. ^ "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  78. ^ "Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
  79. ^ PT. Bio Farma (August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
  80. ^ Chen W, Al Kaabi N (July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
  81. ^ Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Archived from the original on 28 February 2021. Retrieved 11 April 2021.
  82. ^ "Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Archived from the original on 4 November 2021. Retrieved 2 July 2021.
  83. ^ "FarsNews Agency Iran Licenses Emergency Injection of Home-Made Anti-Coronavirus Vaccine". Fars News Agency. 14 June 2021. Archived from the original on 9 October 2021. Retrieved 25 August 2021.